The authors of the expert article published in the Journal of Crohn's and Colitis include major European and North American Key Opinion Leaders in the field of Inflammatory Bowel DiseasesThe KOLs state
Obefazimod global pivotal phase 3 program (ABTECT program) in moderate to severe ulcerative colitis (UC) early enrollment progressing according to planAbivax reports promising Phase 2b maintenance results
Michael Ferguson has a strong track record in the biopharmaceutical industry, having held senior positions for commercialization and marketing of drugs in the field of Gastroenterology and specifically
The analysis demonstrates clinical remission in 52.5% (n=114) of 217 moderate to severe ulcerative colitis (UC) patients (intent-to-treat population, ITT) after two years (96 weeks) of once-daily oral